Dr. Emil Kakkis
CEO of biotechnology company focusing on rare diseases.
Based in CA
AI Overview
With $100K in lobbying spend across 4 quarterly filings, Dr. Emil Kakkis is an active lobbying client. Their lobbying covers 1 issue area. Active from 2023 to 2024.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $50K |
| 2024 | $50K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Dr. Emil Kakkis disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
FDA drug approval process for rare diseases, including increased use of biomarkers in the Accelerated Approval Pathway, clinical trial design and other barriers to approval.
FDA regulatory review and approval issues.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.